Trial Profile
A Phase I trial assessing maximally tolerated dose of sorafenib sorafenib delivered before, during, and after stereotactic body radiation therapy (SBRT) in hepatocellular carinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 30 Jun 2016 New trial record